Please login to the form below

Not currently logged in

FDA approval for Keytruda/Herceptin combination in first-line advanced gastric cancer

Approval is based on positive overall response rate (ORR) data from KEYNOTE-811 trial

The US Food and Drug Administration (FDA) has approved Merck & Co’s Keytruda plus Roche’s Herceptin and chemotherapy in the first-line setting for HER2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma.

The approval is based on data from the ongoing phase 3 KEYNOTE-811 trial, evaluating the Keytruda (pembrolizumab), Herceptin (trastuzumab) and chemotherapy combination in patients with HER2-positive advanced gastric or GEJ adenocarcinoma who had not previously received systemic therapy for metastatic disease.

In this trial, the Keytruda/Herceptin treatment regimen plus either 5-fluorouracil plus cisplatin or capecitabine plus oxaliplatin demonstrated a statistically significant objective response rate (ORR) of 74%, compared with 52% for those who received Herceptin plus chemotherapy alone.

For patients in the Keytruda treatment group, the complete response (CR) rate was 11% and the partial response (PR) rate was 63%, while patients receiving Herceptin and chemotherapy alone achieved a CR rate of 3.1% and a PR rate of 49%.

“[This] approval marks an important milestone, as this is the first time an anti-PD-1 therapy has been approved in combination with anti-HER2 therapy and chemotherapy as a first-line treatment for these patients,” said Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories.

“From the start of Keytruda’s development, we have thoughtfully pursued novel combinations to help more patients with cancer. We are pleased to bring a new first-line combination regimen with Keytruda that has shown meaningful improvement in ORR over standard treatment to patients with HER2-positive gastric and GEJ cancer,” he added.

Article by
Lucy Parsons

6th May 2021

From: Regulatory



COVID-19 Updates and Daily News

Featured jobs


Add my company

OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...

Latest intelligence

The Patient Will See You Now – The Evolution of the Doctor-Patient Relationship
The doctor-patient relationship is an ever changing one that changes as society changes. Technology then helps to drive this change along with a wide number of other factors....
Mind the Gap – Challenging Immunisation Apathy and Misinformation
world, the biggest challenges remain apathy and misinformation. Since a measles vaccine was introduced in the UK in 1968, Public Health England estimates that 20 million measles cases and 4,500...
Towards Better HCP Engagement – An Email Masterclass
6% of HCPs prefer being contacted by email, compared to 17% who favour the second most popular option: direct interaction with reps....